Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915

NOVO NORDISK AS

(NOVO B)
  Report  
Real-time Quote. Real-time CHI-X - 06/25 08:32:40 am
335.475 DKK   +0.46%
06/24NOVO NORDISK : Disclosure of transaction data
PU
06/24NOVO NORDISK A/S : – Share repurchase programme
AQ
06/21NOVO NORDISK : Esperoct approved in the EU
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
06/19/2019 06/20/2019 06/21/2019 06/24/2019 06/25/2019 Date
346.7(c) 340.6(c) 332.95(c) 333.95(c) 335.3 Last
2 613 993 2 912 938 5 376 500 1 784 568 648 119 Volume
-0.37% -1.76% -2.25% +0.30% +0.40% Change
More quotes
Financials (DKK)
Sales 2019 120 B
EBIT 2019 52 007 M
Net income 2019 38 788 M
Finance 2019 13 330 M
Yield 2019 2,49%
Sales 2020 127 B
EBIT 2020 55 387 M
Net income 2020 43 387 M
Finance 2020 15 783 M
Yield 2020 2,76%
P/E ratio 2019 20,39
P/E ratio 2020 17,88
EV / Sales2019 5,08x
EV / Sales2020 4,76x
Capitalization 622 B
More Financials
Company
Novo Nordisk specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84%); - hemophilia treatment products (8.6%): mainly injections of protein; - growth hormones (6.1%):... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk AS
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK AS
04:56aNOVO NORDISK : EMA clears Novo Nordisks long-acting haemophilia A drug
AQ
06/24NOVO NORDISK : Disclosure of transaction data
PU
06/24NOVO NORDISK A/S : – Share repurchase programme
AQ
06/22NOVO NORDISK : Esperoct (turoctocog alfa pegol, N8-GP) approved in the EU
AQ
06/21NOVO NORDISK : Esperoct approved in the EU
AQ
06/20Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU
GL
06/20NOVO NORDISK : FDA approves Novo Nordisks type 2 diabetes drug Victoza
AQ
06/17NOVO NORDISK : FDA Approves Novo Nordisk Treatment for Type 2 Diabetes in Pediat..
DJ
06/14Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece
DJ
06/13Health Care Down on Cyclical Bias -- Health Care Roundup
DJ
More news
Analyst Recommendations on NOVO NORDISK AS
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 2018
Attractive timing with a long term view to go long again
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
07:51aABBVIE : Nears Deal to Buy Allergan for More Than $60 Billion--3rd Update
DJ
07:42aGlobal Stocks Waver as Gold and Bitcoin Soar
DJ
07:39aAbbVie to buy Botox-maker Allergan in $63 billion deal
RE
07:35aAbbVie to buy Botox-maker Allergan in $63 billion deal
RE
07:20aABBVIE : Nears Deal to Buy Allergan for More Than $60 Billion--2nd Update
DJ
More sector news : Pharmaceuticals - NEC
Chart NOVO NORDISK AS
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 343  DKK
Spread / Average Target 2,8%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS12.10%91 011
JOHNSON & JOHNSON10.10%348 981
PFIZER0.05%233 072
ROCHE HOLDING LTD.13.50%227 848
NOVARTIS21.44%220 893
MERCK AND COMPANY11.91%206 641